A mouse study found that the CB2 cannabinoid agonist LY2828360 suppressed chemotherapy-induced neuropathic pain for 12 days without tolerance, prevented morphine tolerance when co-administered, and remained effective in mice already tolerant to morphine.
Pain researchers exploring cannabinoid-opioid interactions; pharmacologists studying biased agonism; oncologists interested in chemotherapy pain management.
12 days of pain relief without tolerance, and morphine tolerance blocked by co-administration
What the researchers found
Researchers characterized LY2828360, a CB2 cannabinoid receptor agonist that had previously failed in a clinical trial for osteoarthritis due to lack of efficacy.
In vitro, LY2828360 was identified as a "G protein-biased" agonist: it activated G protein signaling but did not recruit arrestin, a pattern that may explain its sustained efficacy.
In mice with chemotherapy-induced neuropathic pain (from paclitaxel), LY2828360 at 3 mg/kg/day for 12 days suppressed pain without developing tolerance. The effect was absent in CB2 knockout mice, confirming it worked through CB2 receptors.
When co-administered with morphine, LY2828360 prevented morphine tolerance from developing. LY2828360 also remained effective in mice that were already tolerant to morphine.
There was a trend toward reduced morphine dependence (fewer naloxone-precipitated withdrawal jumps) in mice receiving both drugs.
Why it matters
Opioid tolerance is a major clinical problem: patients need escalating doses for the same pain relief, increasing addiction and overdose risk. A drug that both treats neuropathic pain independently and prevents opioid tolerance could transform pain management, particularly for cancer patients on chemotherapy.
The numbers in context
LY2828360 at 3 mg/kg/day for 12 days: sustained pain relief without tolerance. Co-administration with morphine (10 mg/kg/day): morphine tolerance blocked in wild-type but not CB2 knockout mice. Trend toward reduced withdrawal signs (p = 0.055).
How the study worked
Mouse study using CB2 knockout and wild-type mice. Paclitaxel-induced neuropathic pain model. In vitro receptor characterization (cAMP, ERK1/2, arrestin recruitment, inositol phosphate, receptor internalization). 12-day chronic dosing paradigms.
What this study cannot tell us
Mouse model of chemotherapy pain may not translate directly to human neuropathic pain. LY2828360 previously failed in a human osteoarthritis trial. The trend toward reduced morphine dependence did not reach statistical significance (p = 0.055). CB2 agonists can have immunosuppressive effects not assessed here.
How to read the evidence
Moderate. Well-designed preclinical study with knockout controls and mechanistic characterization, though clinical translation from mouse to human is uncertain.
When this study was published
Published in 2018. G protein-biased CB2 agonism has continued to be an active area of cannabinoid pharmacology research.
The bigger picture
The failure of LY2828360 in an osteoarthritis trial does not mean it is a failed drug. This study suggests it may be effective for a different pain type (neuropathic) and as an adjunct to opioids. The G protein-biased signaling mechanism is increasingly recognized as important for sustained drug efficacy.
Questions still open
- Would LY2828360 show efficacy in human neuropathic pain trials? Can the G protein-biased mechanism be leveraged to develop more effective CB2 drugs? Would combining a CB2 agonist with opioids in human pain management actually reduce opioid tolerance?
Common questions
What does "G protein-biased" mean?
If this drug failed for arthritis pain, why test it for neuropathic pain?
Read the original research
Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence.
Molecular pharmacology, 93(2), 49-62
Citation
Lin, Xiaoyan; Dhopeshwarkar, Amey S; Huibregtse, Megan; Mackie, Ken; Hohmann, Andrea G. (2018). Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence.. Molecular pharmacology, 93(2), 49-62. https://doi.org/10.1124/mol.117.109355
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Physical vs Psychological Cannabis Dependence: What Science Actually Shows
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- The Gap Between Cannabis Perception and Science: Why What We Believe Outpaces What We Know
- Cannabis Use Disorder: Am I Addicted? Self-Assessment Guide
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- Cross-Addiction After Quitting Weed: When One Habit Replaces Another
- Is Weed Addictive? What the Research Actually Shows
- Is Cannabis Addictive? What the DSM-5 and Brain Science Say
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed and Alcohol Together: What to Know About Dual Cessation
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Is Rehab Necessary for Weed? An Honest Assessment
- Cannabis and Older Adults: Risks Seniors Should Know
- Signs You May Have Cannabis Use Disorder: An Honest Self-Assessment
- Cannabis and Breastfeeding: THC in Breast Milk
- Weed Vape Pen Addiction: Why Vaping Makes It Harder to Quit
- THC and Painkillers: Opioid Interactions and the Harm Reduction Angle
- THC and Muscle Relaxers: What You Need to Know About Combining Them
- THC and Ibuprofen: Safe to Combine? What the Research Says